166 related articles for article (PubMed ID: 38004510)
1. Design, Development, Evaluation, and In Vivo Performance of Buccal Films Embedded with Paliperidone-Loaded Nanostructured Lipid Carriers.
AlMulhim FM; Nair AB; Aldhubiab B; Shah H; Shah J; Mewada V; Sreeharsha N; Jacob S
Pharmaceutics; 2023 Oct; 15(11):. PubMed ID: 38004510
[TBL] [Abstract][Full Text] [Related]
2. Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments.
Soni K; Rizwanullah M; Kohli K
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):15-31. PubMed ID: 29183147
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of bioavailability through transdermal drug delivery of paliperidone palmitate-loaded nanostructured lipid carriers.
Raval S; Jani P; Patil P; Thakkar P; Sawant K
Ther Deliv; 2021 Aug; 12(8):583-596. PubMed ID: 34286598
[No Abstract] [Full Text] [Related]
4. Optimization, stabilization, and characterization of amphotericin B loaded nanostructured lipid carriers for ocular drug delivery.
Lakhani P; Patil A; Wu KW; Sweeney C; Tripathi S; Avula B; Taskar P; Khan S; Majumdar S
Int J Pharm; 2019 Dec; 572():118771. PubMed ID: 31669555
[TBL] [Abstract][Full Text] [Related]
5. Combining the potential of 3D printed buccal films and nanostructured lipid carriers for personalised cannabidiol delivery.
Abdella S; Kim S; Afinjuomo F; Song Y; Upton R; Garg S
Drug Deliv Transl Res; 2024 Apr; 14(4):984-1004. PubMed ID: 37903964
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of S(+)-zaltoprofen oral bioavailability using nanostructured lipid carrier system.
Pham TMA; Lee DH; Na YG; Jin M; Jung M; Kim HE; Yoo H; Won JH; Lee JY; Baek JS; Han SC; Lee HK; Cho CW
Arch Pharm Res; 2022 Nov; 45(11):822-835. PubMed ID: 36307644
[TBL] [Abstract][Full Text] [Related]
7. Development of Triamcinolone Acetonide-Loaded Nanostructured Lipid Carriers (NLCs) for Buccal Drug Delivery Using the Box-Behnken Design.
Kraisit P; Sarisuta N
Molecules; 2018 Apr; 23(4):. PubMed ID: 29690622
[TBL] [Abstract][Full Text] [Related]
8. Optimized Nanoparticles for Enhanced Oral Bioavailability of a Poorly Soluble Drug: Solid Lipid Nanoparticles Versus Nanostructured Lipid Carriers.
Darwish MKM; El-Enin ASMA; Mohammed KHA
Pharm Nanotechnol; 2022; 10(1):69-87. PubMed ID: 35142275
[TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of buccal films impregnated with selegiline-loaded nanospheres.
Al-Dhubiab BE; Nair AB; Kumria R; Attimarad M; Harsha S
Drug Deliv; 2016 Sep; 23(7):2154-2162. PubMed ID: 25182182
[TBL] [Abstract][Full Text] [Related]
10. Development of ritonavir-loaded nanostructured lipid carriers employing quality by design (QbD) as a tool: characterizations, permeability, and bioavailability studies.
Gurumukhi VC; Bari SB
Drug Deliv Transl Res; 2022 Jul; 12(7):1753-1773. PubMed ID: 34671949
[TBL] [Abstract][Full Text] [Related]
11. Preparation, characterization, and
Saghafi Z; Mohammadi M; Mahboobian MM; Derakhshandeh K
Drug Dev Ind Pharm; 2021 Mar; 47(3):509-520. PubMed ID: 33650445
[TBL] [Abstract][Full Text] [Related]
12. Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies.
Selvaraj BR; Sridhar SK; Kesavan BR; Palagati S
Pharm Nanotechnol; 2020; 8(6):452-470. PubMed ID: 32988361
[TBL] [Abstract][Full Text] [Related]
13. Optimization of Nanostructured Lipid Carriers of Fenofibrate Using a Box-Behnken Design for Oral Bioavailability Enhancement.
Wang H; Hong W; Li X; Jin Q; Ye W; Feng Y; Huang B; Tai Z; Chen L; Li Z; Wang Y; Yang Y; Gao C; Gong W; Yang M
Curr Drug Deliv; 2022; 19(7):773-787. PubMed ID: 33902411
[TBL] [Abstract][Full Text] [Related]
14. Nanostructured Lipid Carriers to Enhance the Bioavailability and Solubility of Ranolazine: Statistical Optimization and Pharmacological Evaluations.
Unnisa A; Chettupalli AK; Alazragi RS; Alelwani W; Bannunah AM; Barnawi J; Amarachinta PR; Jandrajupalli SB; Elamine BA; Mohamed OA; Hussain T
Pharmaceuticals (Basel); 2023 Aug; 16(8):. PubMed ID: 37631066
[TBL] [Abstract][Full Text] [Related]
15. Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout.
Ali Z; Din FU; Zahid F; Sohail S; Imran B; Khan S; Malik M; Zeb A; Khan GM
BMC Pharmacol Toxicol; 2022 Nov; 23(1):86. PubMed ID: 36443818
[TBL] [Abstract][Full Text] [Related]
16. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: Design and in vivo study.
Shah NV; Seth AK; Balaraman R; Aundhia CJ; Maheshwari RA; Parmar GR
J Adv Res; 2016 May; 7(3):423-34. PubMed ID: 27222747
[TBL] [Abstract][Full Text] [Related]
17. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): An improved dermatokinetic profile for inflammatory disorder(s).
Garg NK; Sharma G; Singh B; Nirbhavane P; Tyagi RK; Shukla R; Katare OP
Int J Pharm; 2017 Jan; 517(1-2):413-431. PubMed ID: 27956192
[TBL] [Abstract][Full Text] [Related]
18. Improved Transmucosal Delivery of Glimepiride via Unidirectional Release Buccal Film Loaded With Vitamin E TPGS-Based Nanocarrier.
Basahih TS; Alamoudi AA; El-Say KM; Alhakamy NA; Ahmed OAA
Dose Response; 2020; 18(3):1559325820945164. PubMed ID: 32782450
[TBL] [Abstract][Full Text] [Related]
19. Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers.
Rizwanullah M; Amin S; Ahmad J
J Drug Target; 2017 Jan; 25(1):58-74. PubMed ID: 27186665
[TBL] [Abstract][Full Text] [Related]
20. Systematic implementation of quality-by-design (QbD) to develop NSAID-loaded nanostructured lipid carriers for ocular application: preformulation screening studies and statistical hybrid-design for optimization of variables.
Rathod VR; Shah DA; Dave RH
Drug Dev Ind Pharm; 2020 Mar; 46(3):443-455. PubMed ID: 32037896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
